H.U. Group Holdings,Inc. Q4 FY2026 earnings call

• Previous Mid-Term Plan Review

  • Most financial and operational targets were missed due to COVID-19 impacts, including delayed H.U. Bioness Complex full operation, unmet fixed cost reduction targets, and missed profit margin and free cash flow targets. Only operating cash flow targets were met, and financial discipline remained healthy.
  • Non-core assets (China JV with Ping An, CRO business) were divested, 12 regional labs were consolidated, and CDMO and NEURO achieved notable growth.

• New Mid-Term Plan "H.U.2030" Core Theme

  • The 5-year plan (2025-2029) is positioned as the "harvest phase" for prior investments, focused on solving outstanding problems from the prior plan, with three core priorities: deepened integrated management, transformation to a high-profit business model, and optimized capital allocation with improved capital efficiency.

• LTS Segment Strategic Priorities

  • Split into two phases: 2025-2026 for structural transformation to build a profit-generating business model, followed by profitable growth from 2027 onwards. Cancelled the planned new Kansai lab, opting for facility modification and layout adjustment to meet capacity needs.
  • Prioritize maximizing functionality of H.U. Bioness Complex: implement process optimization via data analysis to reduce pre-processing time, prevent errors, and increase capacity to over 250,000 IDs by 2029; introduce automation and AI for special and genetic testing to improve efficiency and quality.
  • Develop in-house high-value-added test items directly tied to diagnosis and treatment; target 20%+ reagent cost reduction for in-house developed genetic tests, with potential future external reagent sales.

• IVD Segment Strategic Priorities

  • Maintain existing strategy combining in-house Lumipulse products and CDMO, with continued investment of 12%+ of IVD revenue in R&D to develop unique, market-leading products.
  • CDMO: Expand geographic reach via new partnerships, such as the collaboration with India's Agappe Diagnostics to support expansion into India and emerging markets across South Asia, Southeast Asia, Middle East, and Africa.
  • NEURO: Accelerate sales of pTau217 and β-amyloid 1-42 Alzheimer's disease reagents after FDA approval, target 5+ new test items per year for the Lumipulse platform, and leverage ADx NeuroSciences assets for growth, with a 20%+ CAGR target for the NEURO business.
  • Prioritize ultra-sensitive detection reagent development for unmet needs including tuberculosis and hepatitis, targeting CDMO partnerships with global IVD players.

• Capital Allocation and Shareholder Return

  • Adopt a progressive dividend policy, maintain a 6% DOE target, and plan for over 20 billion yen in total share buybacks over the 5-year plan period, with total shareholder return expected to exceed 56 billion yen.
  • Prioritize ROIC-focused management, target ROE and consolidated ROIC 2%+ above the 7-8% cost of equity by 2027, maintain financial discipline with a net debt/EBITDA (excluding lease liabilities) target below 1.3x and 40%+ equity ratio.
  • M&A can be supported by available spare debt capacity after maintaining financial discipline.

• Leadership Succession Plan

  • Four internal candidates for next CEO have been shortlisted; the new CEO will be selected by January 2026 and take office by April 2026. A management innovation project with all four candidates will launch in June 2025 to refine the mid-term plan, which will form the basis for candidate assessment.

The transcript only provides 2029 end-of-period target performance for each segment, with no current period absolute or percentage contribution data:

1. LTS (Laboratory Testing Services): Target 3%+ CAGR for revenue through 2029, target 10%+ operating margin by 2029. Depreciation is set to peak at 13 billion yen in 2025, falling by 4.5 billion yen by 2027 and 6 billion yen by 2029.
2. IVD (In-Vitro Diagnostics): Target 6%+ CAGR for overseas revenue through 2029, target 25%+ operating margin by 2029. NEURO Alzheimer's disease test reagents grew from 0.6 billion yen in 2020 to 4.7 billion yen in 2024. CDMO grew from 2 partners/17 projects in 2019 to 6 partners/55 projects in 2024.
3. HS (Sterilization & Surgery-related Services): Targets profit-focused growth, with a focus on high-value, high-difficulty surgery-related services to achieve higher ROIC.

• Consolidated 2029 Targets: 16%+ EBITDA margin, 11%+ operating margin, 10%+ consolidated ROIC, 13%+ ROE, cumulative operating cash flow of over 150 billion yen for the 5-year period.
• Segment 2029 Targets: LTS targets 3%+ revenue CAGR and 10%+ operating margin; IVD targets 6%+ overseas revenue CAGR and 25%+ operating margin; NEURO targets 20%+ total revenue CAGR.
• Capital Expenditure and Depreciation: Total capital expenditure over 5 years will be 40 billion yen, mostly for maintenance, with capex peaking in 2025 before declining. Depreciation will peak in 2025, with a 5 billion yen reduction expected by 2027.
• R&D Investment: 12%+ of IVD segment revenue will be continuously invested in R&D, consistent with prior strategy.

• H.U. Bioness Complex transfer and operation took longer than expected, leading to prior fixed cost reduction targets being missed, and full profitability improvements depend on successful operational optimization over the next two years.
• CDMO revenue growth depends on partner regulatory approval timelines, which have inherent time lags and uncertainty that could lead to slower-than-expected revenue realization.
• Changing healthcare trends including hospital consolidation and the shift to home healthcare could alter testing demand patterns, requiring ongoing strategic adjustment for the LTS business.
• The Alzheimer's blood testing market is at an early stage of development, and competitive dynamics or the emergence of new alternative biomarkers could change the competitive landscape.

Q: The NEURO growth chart shows smaller-than-expected CDMO contribution. What explains this breakdown, and what is the competitive landscape for Alzheimer's blood testing? / A: CDMO revenue only includes income from supplying raw materials and reagents to partners, who sell the final product to end users, so CDMO only accounts for a portion of total market revenue. While CDMO has high margins, growth depends on how quickly partners expand the market globally; the current chart reflects the current baseline expectation, and the CDMO segment will grow faster than projected if expansion accelerates. H.U. Group's competitive advantage comes from its existing installed base of Lumipulse instruments in the U.S. and Europe that can already run the tests, with high processing capacity and strong user feedback. The company views market expansion as a collaborative effort with partners rather than purely competitive.

Q: What is the rationale for the 10% operating margin target for LTS, given capacity increases and changing external market conditions? / A: The 10% target reflects the large structural cost reductions from consolidating legacy decentralized labs into H.U. Bioness Complex, which eliminates high overhead costs from fragmented operations. Additionally, in-house production of reagents via group synergies is expected to deliver double-digit cost improvements compared to third-party reagents. Management expects growing demand for high-margin specialty testing from hospital consolidation, which will offset any pressure from the shift to home healthcare, justifying the 10% target.

Q: Why release the mid-term plan before selecting the new CEO, and what is the rationale for using this plan as the basis for the succession process? / A: The plan contains many time-sensitive initiatives that require immediate implementation to improve corporate value, so delaying the launch until after leadership succession would hurt performance. The plan was developed by current executive officers, which include all four CEO candidates, so all candidates already have ownership of the plan. The management innovation project during the selection process will allow candidates to refine and deepen the plan, so whoever is selected will lead a plan they helped co-develop.

Q: What is the outlook for competitive dynamics in the Alzheimer's blood testing market, and how sustainable is H.U. Group's first-mover advantage? / A: H.U. Group's first-mover advantage allows it to immediately capture demand from installed Lumipulse instruments that are already in routine use. The company will pursue direct sales in markets where it has installed capacity, and expand the market broadly via CDMO partnerships given limits to direct installation growth. The market is still in an early stage, so the company will continue R&D to develop additional Alzheimer's and neurodegenerative disease test candidates in parallel with growing sales of its currently approved products.